{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:59:56Z","timestamp":1793764796014,"version":"4.6.1"},"reference-count":347,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017578","name":"Mainzer Herz Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"German Center for Cardiovascular Disease","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius Foundation","doi-asserted-by":"publisher","award":["2021_EKES04"],"award-info":[{"award-number":["2021_EKES04"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.pharmr.2025.100082","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:56:13Z","timestamp":1752573373000},"page":"100082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases"],"prefix":"10.1016","volume":"77","author":[{"given":"Sebastian","family":"Steven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-851X","authenticated-orcid":false,"given":"Marin","family":"Kuntic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-0094","authenticated-orcid":false,"given":"Andreas","family":"Daiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib1","article-title":"History of insulin","volume":"2","author":"Quianzon","year":"2012","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.pharmr.2025.100082_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bios.2019.03.010","article-title":"Methylglyoxal\u2014an emerging biomarker for diabetes mellitus diagnosis and its detection methods","volume":"133","author":"Ramachandra Bhat","year":"2019","journal-title":"Biosens Bioelectron"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib3","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2337\/dc21-0770","article-title":"Adult-onset type 1 diabetes: current understanding and challenges","volume":"44","author":"Leslie","year":"2021","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.pharmr.2025.100082_bib4","first-page":"S20","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"10159","key":"10.1016\/j.pharmr.2025.100082_bib5","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Injury","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100082_bib6","series-title":"International Diabetes Federation, IDF Diabetes Atlas","year":"2021"},{"issue":"9859","key":"10.1016\/j.pharmr.2025.100082_bib7","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"issue":"9859","key":"10.1016\/j.pharmr.2025.100082_bib8","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)61899-6","article-title":"GBD 2010: design, definitions, and metrics","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/01.hjr.0000183916.28354.69","article-title":"Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study","volume":"13","author":"Nakagami","year":"2006","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100082_bib10","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch Intern Med"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100082_bib11","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1161\/CIR.0000000000000450","article-title":"Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the american heart association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4254\/wjh.v12.i7.378","article-title":"Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study","volume":"12","author":"Ghoneim","year":"2020","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/pharmrev.121.000348","article-title":"Interaction of cardiovascular nonmodifiable risk factors, comorbidities and comedications with ischemia\/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning","volume":"75","author":"Ferdinandy","year":"2023","journal-title":"Pharmacol Rev"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib14","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.2337\/dc18-1179","article-title":"Economic costs attributable to diabetes in each U.S. state","volume":"41","author":"Shrestha","year":"2018","journal-title":"Diabetes Care"},{"issue":"10258","key":"10.1016\/j.pharmr.2025.100082_bib16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"9131","key":"10.1016\/j.pharmr.2025.100082_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100082_bib18","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib19","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"64","author":"Holt","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2025.100082_bib20","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/ncomms3192","article-title":"Metformin improves healthspan and lifespan in mice","volume":"4","author":"Martin-Montalvo","year":"2013","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/antiox9060525","article-title":"The AMP-activated protein kinase plays a role in antioxidant defense and regulation of vascular inflammation","volume":"9","author":"Jansen","year":"2020","journal-title":"Antioxidants"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.cmet.2014.09.013","article-title":"AMPK--sensing energy while talking to other signaling pathways","volume":"20","author":"Hardie","year":"2014","journal-title":"Cell Metabol"},{"key":"10.1016\/j.pharmr.2025.100082_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1475-2840-8-38","article-title":"A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease","volume":"8","author":"Fisman","year":"2009","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis","volume":"18","author":"Han","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100082_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007638","article-title":"Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/dom.12821","article-title":"Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data","volume":"19","author":"Bain","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib27","first-page":"381","article-title":"Long-term risk of rosiglitazone on cardiovascular events\u2014a systematic review and meta-analysis","volume":"69","author":"Cheng","year":"2018","journal-title":"Endokrynol Pol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12933-017-0512-z","article-title":"Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes","volume":"16","author":"Zhang","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40360-019-0293-y","article-title":"Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis","volume":"20","author":"Liu","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.pharmr.2025.100082_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7092151","article-title":"Vascular inflammation and oxidative stress: major triggers for cardiovascular disease","volume":"2019","author":"Steven","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.pharmr.2025.100082_bib32","series-title":"Diabetes\u2014Oxidative Stress and Dietary Antioxidants","first-page":"1","article-title":"SGLT2 inhibitors, diabetes and oxidative stress","author":"Steven","year":"2020"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib33","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/bph.13517","article-title":"Targeting vascular (endothelial) dysfunction","volume":"174","author":"Daiber","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib34","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/bph.13403","article-title":"Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function","volume":"174","author":"Daiber","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100082_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2017.01.027","article-title":"Redox regulation of cardiovascular inflammation\u2014Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species","volume":"109","author":"Wenzel","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib36","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.3390\/ijms21103405","article-title":"Regulation of vascular function and inflammation via cross talk of reactive oxygen and nitrogen species from mitochondria or NADPH oxidase-implications for diabetes progression","volume":"21","author":"Daiber","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100082_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102894","article-title":"Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection","volume":"67","author":"Heusch","year":"2023","journal-title":"Redox Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.81.2.491","article-title":"Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease","volume":"81","author":"Vita","year":"1990","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM199007053230105","article-title":"Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension","volume":"323","author":"Panza","year":"1990","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100082_bib40","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/01.CIR.0000012543.55874.47","article-title":"Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study","volume":"105","author":"Gokce","year":"2002","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib41","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0735-1097(03)00333-4","article-title":"Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease","volume":"41","author":"Gokce","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib42","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1172\/JCI116149","article-title":"Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes","volume":"90","author":"Calver","year":"1992","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib43","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/01.ATV.0000215951.36219.a4","article-title":"Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study","volume":"26","author":"de Jager","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib44","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s001250051551","article-title":"Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus","volume":"43","author":"Heitzer","year":"2000","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0891-5849(01)00551-2","article-title":"Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress","volume":"31","author":"Heitzer","year":"2001","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmr.2025.100082_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2337\/diacare.19.3.257","article-title":"Oxidative stress and diabetic vascular complications","volume":"19","author":"Giugliano","year":"1996","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM198703053161007","article-title":"Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications","volume":"316","author":"Greene","year":"1987","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib49","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: sparking the development of diabetic vascular injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmr.2025.100082_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mvr.2014.06.010","article-title":"Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications","volume":"95","author":"Chawla","year":"2014","journal-title":"Microvasc Res"},{"issue":"6779","key":"10.1016\/j.pharmr.2025.100082_bib51","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/35008121","article-title":"Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage","volume":"404","author":"Nishikawa","year":"2000","journal-title":"Nature"},{"issue":"3-4","key":"10.1016\/j.pharmr.2025.100082_bib52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/03008208209008054","article-title":"Glycosylation of human glomerular basement membrane collagen: increased content of hexose in ketoamine linkage and unaltered hydroxylysine-O-glycosides in patients with diabetes","volume":"10","author":"Uitto","year":"1982","journal-title":"Connect Tissue Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib53","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI115014","article-title":"Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes","volume":"87","author":"Bucala","year":"1991","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib54","doi-asserted-by":"crossref","first-page":"E685","DOI":"10.1152\/ajpendo.2001.280.5.E685","article-title":"Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE","volume":"280","author":"Wautier","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib55","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1681\/ASN.2008050514","article-title":"RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes","volume":"20","author":"Coughlan","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100082_bib56","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/01.CIR.0000039325.03698.36","article-title":"RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice","volume":"106","author":"Bucciarelli","year":"2002","journal-title":"Circulation"},{"issue":"6865","key":"10.1016\/j.pharmr.2025.100082_bib57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/138161208783597416","article-title":"Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication","volume":"14","author":"Yamagishi","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pharmr.2025.100082_bib59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejphar.2018.06.001","article-title":"AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions","volume":"833","author":"Sanajou","year":"2018","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib60","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcjd.2021.01.004","article-title":"Association between soluble receptor for advanced glycation end product and endogenous secretory soluble receptor for advanced glycation end product levels and carotid atherosclerosis in diabetes: a systematic review and meta-analysis","volume":"45","author":"Wang","year":"2021","journal-title":"Can J Diabetes"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100082_bib61","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/hc4601.099485","article-title":"Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease","volume":"104","author":"Heitzer","year":"2001","journal-title":"Circulation"},{"issue":"3A","key":"10.1016\/j.pharmr.2025.100082_bib62","doi-asserted-by":"crossref","first-page":"7A","DOI":"10.1016\/S0002-9149(02)03144-2","article-title":"Role of oxidative stress in atherosclerosis","volume":"91","author":"Harrison","year":"2003","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib63","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00395-024-01055-z","article-title":"Vasodilator reactive oxygen species ameliorate perturbed myocardial oxygen delivery in exercising swine with multiple comorbidities","volume":"119","author":"van Drie","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmr.2025.100082_bib64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12916-015-0537-7","article-title":"Evidence for the free radical\/oxidative stress theory of ageing from the CHANCES consortium: a meta-analysis of individual participant data","volume":"13","author":"Schottker","year":"2015","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib65","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.freeradbiomed.2005.06.018","article-title":"Oxidative stress and diabetic cardiovascular complications","volume":"40","author":"Jay","year":"2006","journal-title":"Free Radic Biol Med"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100082_bib66","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008226","article-title":"Relationship between plasma 8-OH-deoxyguanosine and cardiovascular disease and survival in type 2 diabetes mellitus: results from the ADVANCE trial","volume":"7","author":"Thomas","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib67","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2337\/dc17-1150","article-title":"Cardiovascular and all-cause mortality risk associated with urinary excretion of 8-oxoGuo, a biomarker for RNA oxidation, in patients with type 2 diabetes: a prospective cohort study","volume":"40","author":"Kjaer","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-024-01045-1","article-title":"Role of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in diabetes and hypertension-insights from animal and human studies","volume":"119","author":"Strohm","year":"2024","journal-title":"Basic Res Cardiol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100082_bib69","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100082_bib70","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"issue":"10118","key":"10.1016\/j.pharmr.2025.100082_bib71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2004.01.002","article-title":"Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. Comparative Study","volume":"174","author":"Henry","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmr.2025.100082_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2024.106887","article-title":"The effects of omega-3 fatty acids on inflammatory and oxidative stress markers in patients with Type 2 diabetes mellitus: a systematic review and meta-analysis of controlled trials","volume":"175","author":"Muzammil","year":"2024","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib74","doi-asserted-by":"crossref","first-page":"18185","DOI":"10.3390\/ijms160818185","article-title":"Exploiting the pleiotropic antioxidant effects of established drugs in cardiovascular disease","volume":"16","author":"Steven","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib75","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/HYPERTENSIONAHA.110.163576","article-title":"Inflammation, immunity, and hypertension","volume":"57","author":"Harrison","year":"2011","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/jmcc.1998.0843","article-title":"Endothelial dysfunction in human disease","volume":"31","author":"Drexler","year":"1999","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib77","first-page":"38","article-title":"Why do antioxidants fail to provide clinical benefit?","volume":"1","author":"Warnholtz","year":"2000","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib78","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1476-5381.1994.tb14787.x","article-title":"Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor","volume":"111","author":"Porsti","year":"1994","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib79","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1161\/01.ATV.0000190673.41925.9B","article-title":"Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy","volume":"25","author":"Mollnau","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/FJC.0b013e318063e820","article-title":"NADPH oxidase inhibitors: new antihypertensive agents?","volume":"50","author":"Williams","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib81","first-page":"1605","article-title":"Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat","volume":"36","author":"Caspritz","year":"1986","journal-title":"Arzneimittel-Forschung"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib82","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11239-004-0205-9","article-title":"Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation","volume":"18","author":"Ray","year":"2004","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib84","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/eurheartj\/ehl445","article-title":"A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis","volume":"28","author":"Patel","year":"2007","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib85","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1089\/ars.2013.5526","article-title":"Rac1-mediated effects of HMG-CoA reductase inhibitors (statins) in cardiovascular disease","volume":"20","author":"Adam","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib86","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.atherosclerosis.2007.10.003","article-title":"Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus","volume":"198","author":"Wenzel","year":"2008","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib87","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1089\/ars.2013.5430","article-title":"Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering","volume":"20","author":"Margaritis","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib88","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00109-008-0393-4","article-title":"Simvastatin activates Keap1\/Nrf2 signaling in rat liver","volume":"86","author":"Habeos","year":"2008","journal-title":"J Mol Med"},{"issue":"28","key":"10.1016\/j.pharmr.2025.100082_bib89","doi-asserted-by":"crossref","first-page":"18882","DOI":"10.1074\/jbc.M109.009886","article-title":"Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow","volume":"284","author":"Ali","year":"2009","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib90","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/FJC.0b013e3182a4027f","article-title":"The effect of statins on circulating endothelial progenitor cells in humans: a systematic review","volume":"62","author":"Hibbert","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00395-024-01046-0","article-title":"Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin","volume":"120","author":"Efentakis","year":"2025","journal-title":"Basic Res Cardiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib92","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacc.2011.07.053","article-title":"A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice","volume":"59","author":"Matsubara","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular biology of the incretin system","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr Rev"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100082_bib94","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib95","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.atherosclerosis.2013.08.033","article-title":"Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe(-)\/(-) mice","volume":"231","author":"Burgmaier","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1479164111404257","article-title":"A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-\/- mouse model","volume":"8","author":"Gaspari","year":"2011","journal-title":"Diab Vasc Dis Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib97","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib98","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1161\/CIRCULATIONAHA.111.034470","article-title":"Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction","volume":"124","author":"Wenzel","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100082_bib99","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00210-015-1124-3","article-title":"Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes\/macrophages","volume":"388","author":"Buldak","year":"2015","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib100","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100082_bib101","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","article-title":"Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor","volume":"325","author":"Erdogdu","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100082_bib102","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Comparative Study","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib103","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.abb.2008.08.001","article-title":"GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP","volume":"478","author":"Green","year":"2008","journal-title":"Arch Biochem Biophys"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100082_bib104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.vph.2011.03.001","article-title":"Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways","volume":"55","author":"Shah","year":"2011","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cvr\/cvs246","article-title":"Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition","volume":"96","author":"Kroller-Schon","year":"2012","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib106","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FJC.0000000000000255","article-title":"Effect of Glucagon-like peptide-1 on high-glucose-induced oxidative stress and cell apoptosis in human endothelial cells and its underlying mechanism","volume":"66","author":"Wang","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib107","first-page":"288","article-title":"Gastrointestinal incretins-glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) beyond pleiotropic physiological effects are involved in pathophysiology of atherosclerosis and coronary artery disease-state of the art","volume":"11","author":"Jonik","year":"2022","journal-title":"Biology (Basel)"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pharmr.2025.100082_bib109","article-title":"Anti-atherosclerotic effect of incretin receptor agonists","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib110","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib111","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/ATVBAHA.110.206425","article-title":"Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A","volume":"30","author":"Oeseburg","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib112","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejps.2012.07.003","article-title":"Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats","volume":"47","author":"Akarte","year":"2012","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib113","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2013.10.025","article-title":"Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells","volume":"232","author":"Batchuluun","year":"2014","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib114","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijcard.2012.01.011","article-title":"Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury","volume":"167","author":"Chinda","year":"2013","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib116","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1113\/EP085108","article-title":"Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction","volume":"100","author":"Inthachai","year":"2015","journal-title":"Exp Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib117","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jvs.2013.04.048","article-title":"Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats","volume":"59","author":"Bao","year":"2014","journal-title":"J Vasc Surg"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib118","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways","volume":"133","author":"Abdelsalam","year":"2015","journal-title":"J Neurochem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib119","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","article-title":"Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia","volume":"110","author":"Steven","year":"2015","journal-title":"Basic Res Cardiol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib121","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3390\/antiox11071418","article-title":"Antioxidant effects of DPP-4 inhibitors in early stages of experimental diabetic retinopathy","volume":"11","author":"Ramos","year":"2022","journal-title":"Antioxidants"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib122","doi-asserted-by":"crossref","first-page":"E1163","DOI":"10.1210\/jc.2013-1029","article-title":"The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization","volume":"98","author":"Shah","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib123","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2337\/dc12-0199","article-title":"Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition","volume":"35","author":"Rizzo","year":"2012","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib124","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.4049\/jimmunol.155.10.4630","article-title":"Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule","volume":"155","author":"Martin","year":"1995","journal-title":"J Immunol"},{"issue":"5120","key":"10.1016\/j.pharmr.2025.100082_bib125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.8101391","article-title":"Direct association of adenosine deaminase with a T cell activation antigen, CD26","volume":"261","author":"Kameoka","year":"1993","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib126","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.atherosclerosis.2012.09.012","article-title":"An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease","volume":"226","author":"Zhong","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib127","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib128","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1038\/s41467-020-17556-z","article-title":"Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans","volume":"11","author":"Baggio","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmstadter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2025.100082_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2015.01.002","article-title":"Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study","volume":"81","author":"Ravassa","year":"2015","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib131","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","article-title":"Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes","volume":"17","author":"Lambadiari","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib132","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCRESAHA.109.201590","article-title":"Activation and signaling by the AMP-activated protein kinase in endothelial cells","volume":"105","author":"Fisslthaler","year":"2009","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib133","doi-asserted-by":"crossref","first-page":"H1120","DOI":"10.1152\/ajpheart.00210.2014","article-title":"AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes","volume":"307","author":"Balteau","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib134","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor","volume":"179","author":"Helmstadter","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"10019","key":"10.1016\/j.pharmr.2025.100082_bib135","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2025.100082_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173318","article-title":"Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR\/p70S6K signaling and promoting autophagy","volume":"883","author":"Zheng","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","article-title":"Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages","volume":"111","author":"Tate","year":"2016","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib138","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1160\/TH16-07-0586","article-title":"Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation","volume":"117","author":"Barale","year":"2017","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib139","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1161\/ATVBAHA.119.313645","article-title":"Native, intact glucagon-like peptide 1 is a natural suppressor of thrombus growth under physiological flow conditions","volume":"40","author":"Sternkopf","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib140","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis","volume":"65","author":"Cameron-Vendrig","year":"2016","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib141","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/bph.13549","article-title":"Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice","volume":"174","author":"Steven","year":"2017","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib142","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dbi16-0014","article-title":"Glucagon-like peptide 1 receptor activation and platelet function: beyond glycemic control","volume":"65","author":"Jia","year":"2016","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2022.108188","article-title":"A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study)","volume":"36","author":"Loganathan","year":"2022","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.pharmr.2025.100082_bib144","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2147\/DDDT.S312347","article-title":"Effects of exenatide on coagulation and platelet aggregation in patients with type 2 diabetes","volume":"15","author":"Zhang","year":"2021","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib145","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/antiox11101878","article-title":"The sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce platelet activation and thrombus formation by lowering NOX2-related oxidative stress: a pilot study","volume":"11","author":"Pignatelli","year":"2022","journal-title":"Antioxidants"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib146","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.2300102","article-title":"Glucagon-like peptide-1 receptor pathway attenuates platelet activation in aspirin-exacerbated respiratory disease","volume":"211","author":"Foer","year":"2023","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib147","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101398","article-title":"Novel therapeutic strategies to reduce reperfusion injury after acute myocardial infarction","volume":"47","author":"Schafer","year":"2022","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib149","first-page":"774","article-title":"The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge","volume":"38","author":"Heusch","year":"2017","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib150","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","article-title":"Myocardial ischaemia-reperfusion injury and cardioprotection in perspective","volume":"17","author":"Heusch","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib151","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury","volume":"53","author":"Timmers","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib152","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib161","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3390\/ph16060836","article-title":"Multifaceted roles of GLP-1 and Its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective","volume":"16","author":"Pandey","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib153","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.medj.2023.12.007","article-title":"Myocardial ischemia\/reperfusion: Translational pathophysiology of ischemic heart disease","volume":"5","author":"Heusch","year":"2024","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib154","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1172\/JCI99934","article-title":"Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-alpha","volume":"130","author":"Siraj","year":"2020","journal-title":"J Clin Invest"},{"issue":"1-3","key":"10.1016\/j.pharmr.2025.100082_bib155","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.regpep.2007.10.001","article-title":"Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart","volume":"146","author":"Sonne","year":"2008","journal-title":"Regul Pept"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib156","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00395-023-00992-5","article-title":"The RISK pathway leading to mitochondria and cardioprotection: how everything started","volume":"118","author":"Yellon","year":"2023","journal-title":"Basic Res Cardiol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib157","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1210\/me.2014-1346","article-title":"Epac is required for GLP-1R-mediated inhibition of oxidative stress and apoptosis in cardiomyocytes","volume":"29","author":"Mangmool","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100082_bib158","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fphar.2020.00805","article-title":"Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac\/PI3K\/Akt pathway","volume":"11","author":"Nuamnaichati","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib159","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1536\/ihj.19-327","article-title":"Exendin-4 reduces ventricular arrhythmia activity and calcium sparks-mediated sarcoplasmic reticulum Ca leak in rats with heart failure","volume":"61","author":"Chen","year":"2020","journal-title":"Int Heart J"},{"key":"10.1016\/j.pharmr.2025.100082_bib160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijcard.2015.12.009","article-title":"Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction","volume":"208","author":"Chen","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib162","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/cvr\/cvs123","article-title":"GLP-1 and cardioprotection: from bench to bedside","volume":"94","author":"Ravassa","year":"2012","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib163","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.118.006740","article-title":"Modulation of cardiac ventricular excitability by GLP-1 (glucagon-like peptide-1)","volume":"11","author":"Ang","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib164","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/aps.2014.98","article-title":"Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors","volume":"36","author":"Chang","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib165","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2337\/db12-1239","article-title":"Aging and insulin resistance: just say iNOS","volume":"62","author":"Evans","year":"2013","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib166","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib167","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pcd.2023.10.010","article-title":"Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials","volume":"18","author":"Nan","year":"2024","journal-title":"Prim Care Diabetes"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112394","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity","volume":"9","author":"Oelze","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib169","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067009","article-title":"Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats","volume":"8","author":"Kumar","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib174","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.3390\/ijms24076039","article-title":"Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control","volume":"24","author":"Youssef","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib175","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/kidneydial2020032","article-title":"The pathophysiological basis of diabetic kidney protection by inhibition of SGLT2 and SGLT1","volume":"2","author":"Oe","year":"2022","journal-title":"Kidney Dial"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib170","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nm.2750","article-title":"Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy","volume":"18","author":"Bierhaus","year":"2012","journal-title":"Nat Med"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100082_bib171","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1073\/pnas.91.16.7742","article-title":"Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications","volume":"91","author":"Wautier","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib172","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/10715762.2023.2213820","article-title":"Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials","volume":"57","author":"Larsen","year":"2023","journal-title":"Free Radic Res"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib173","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00392-023-02164-w","article-title":"Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial","volume":"112","author":"Prochaska","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib176","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/dom.14196","article-title":"A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?","volume":"22","author":"Vincent","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib177","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2152\/jmi.67.280","article-title":"Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus","volume":"67","author":"Shinozaki","year":"2020","journal-title":"J Med Invest"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib178","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.pharmr.2025.100082_bib179","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib180","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib181","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00395-022-00934-7","article-title":"Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia\/reperfusion injury: a class or a drug effect?","volume":"117","author":"Nikolaou","year":"2022","journal-title":"Basic Res Cardiol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib182","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2019.7923","article-title":"Chronic empagliflozin treatment reduces myocardial infarct size in nondiabetic mice through STAT-3-mediated protection on microvascular endothelial cells and reduction of oxidative stress","volume":"34","author":"Nikolaou","year":"2021","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165770","article-title":"SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models","volume":"1866","author":"Andreadou","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib184","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.124.324708","article-title":"SGLT2 inhibition induces cardioprotection by increasing parasympathetic activity","volume":"136","author":"Basalay","year":"2025","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib185","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100082_bib186","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.3390\/ijms25137274","article-title":"Endothelial protection by sodium-glucose cotransporter 2 inhibitors: a literature review of in vitro and in vivo studies","volume":"25","author":"Mylonas","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib187","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","article-title":"The pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: beyond the glycemic benefit","volume":"10","author":"Patel","year":"2019","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib188","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/HCO.0000000000000922","article-title":"The pleiotropic cardiovascular effects of sodium-glucose cotransporter-2 inhibitors","volume":"36","author":"Tanna","year":"2021","journal-title":"Curr Opin Cardiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib189","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/jcm12082824","article-title":"Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors in cardiovascular disease and chronic kidney disease","volume":"12","author":"Rastogi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.pharmr.2025.100082_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109927","article-title":"Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes","volume":"188","author":"Theofilis","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib191","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.3390\/molecules25122757","article-title":"The off-target effects, electrolyte and mineral disorders of SGLT2i","volume":"25","author":"Cianciolo","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmr.2025.100082_bib192","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2147\/DMSO.S258593","article-title":"Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice","volume":"13","author":"Nguyen","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100082_bib193","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/cvr\/cvae156","article-title":"Crucial role for sensory nerves and Na\/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation","volume":"120","author":"Forrester","year":"2024","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib194","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/cvr\/cvae257","article-title":"SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance","volume":"121","author":"Mroueh","year":"2025","journal-title":"Cardiovasc Res"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100082_bib195","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035044","article-title":"Empagliflozin attenuates neointima formation after arterial injury and inhibits smooth muscle cell proliferation and migration by suppressing platelet-derived growth factor-related signaling","volume":"13","author":"Chang","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pharmr.2025.100082_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101527","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1","volume":"32","author":"Behnammanesh","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.pharmr.2025.100082_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109825","article-title":"The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1beta and IL-18 secretion","volume":"77","author":"Sukhanov","year":"2021","journal-title":"Cell Signal"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib198","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib199","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: a multimodality study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pharmr.2025.100082_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175720","article-title":"Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function","volume":"949","author":"Dasari","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib201","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFbeta1\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovas Diabetol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib203","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12933-023-01754-2","article-title":"Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors","volume":"22","author":"Scisciola","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.pharmr.2025.100082_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150254","article-title":"Dapagliflozin administration to a mouse model of type 2 diabetes induces DNA methylation and gene expression changes in pancreatic islets","volume":"725","author":"Yokoi","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmr.2025.100082_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrgentox.2024.503765","article-title":"Dapagliflozin suppresses diabetes-induced oxidative DNA damage and hypermethylation in mouse somatic cells","volume":"896","author":"Attia","year":"2024","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"10.1016\/j.pharmr.2025.100082_bib206","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jad.2024.05.150","article-title":"Empagliflozin alleviates neuroinflammation by inhibiting astrocyte activation in the brain and regulating gut microbiota of high-fat diet mice","volume":"360","author":"Huang","year":"2024","journal-title":"J Affect Disord"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib207","article-title":"Effect of dapagliflozin on ferroptosis through the gut microbiota metabolite TMAO during myocardial ischemia-reperfusion injury in diabetes mellitus rats","volume":"14","author":"Wang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100082_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106598","article-title":"Sotagliflozin attenuates cardiac dysfunction and depression-like behaviors in mice with myocardial infarction through the gut-heart-brain axis","volume":"199","author":"Liao","year":"2024","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib209","doi-asserted-by":"crossref","first-page":"C994","DOI":"10.1152\/ajpcell.00367.2024","article-title":"Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis","volume":"327","author":"Lei","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmr.2025.100082_bib210","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1447327","article-title":"Fine mapping-based multi-omics analysis interprets the gut-lung axis function of SGLT2 inhibitors","volume":"14","author":"Yuan","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib211","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jacbts.2024.08.010","article-title":"The enigmata of cardioprotection with SGLT2 inhibition","volume":"10","author":"Heusch","year":"2025","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib212","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacbts.2024.08.003","article-title":"Empagliflozin in acute myocardial infarction reduces no-reflow and preserves cardiac function by preventing endothelial damage","volume":"10","author":"Nikolaou","year":"2025","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-022-00909-8","article-title":"Coronary blood flow in heart failure: cause, consequence and bystander","volume":"117","author":"Heusch","year":"2022","journal-title":"Basic Res Cardiol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100082_bib214","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100082_bib215","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100082_bib216","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib217","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib218","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100082_bib219","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100082_bib220","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1046\/j.1432-1327.2000.01617.x","article-title":"Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8","volume":"267","author":"Abbott","year":"2000","journal-title":"Eur J Biochem"},{"issue":"1-2","key":"10.1016\/j.pharmr.2025.100082_bib221","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0165-2478(94)00230-O","article-title":"Functional role of CD26 on human B lymphocytes","volume":"45","author":"Buhling","year":"1995","journal-title":"Immunol Lett"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib222","first-page":"270","article-title":"Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells","volume":"13","author":"Buhling","year":"1994","journal-title":"Nat Immun"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib223","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/CS20040302","article-title":"Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders","volume":"108","author":"Gorrell","year":"2005","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmr.2025.100082_bib224","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-1-4615-9543-4_45","article-title":"Dipeptidyl(amino)peptidase IV and post proline cleaving enzyme in cultured endothelial and smooth muscle cells","volume":"247A","author":"Palmieri","year":"1989","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib225","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP. Review","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib226","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1073\/pnas.79.2.345","article-title":"Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem","volume":"79","author":"Lund","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib227","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol Therap"},{"issue":"1 Suppl","key":"10.1016\/j.pharmr.2025.100082_bib228","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2010.11.002","article-title":"Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications","volume":"124","author":"Nauck","year":"2011","journal-title":"Am J Medicine"},{"issue":"3-4","key":"10.1016\/j.pharmr.2025.100082_bib229","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/10606820213687","article-title":"Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. A","volume":"8","author":"Brubaker","year":"2002","journal-title":"Rec channel"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib231","first-page":"3585","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib232","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038744","article-title":"Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity","volume":"7","author":"Kern","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib233","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2337\/db12-0988","article-title":"The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride","volume":"62","author":"Darsalia","year":"2013","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib234","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000333358","article-title":"Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis","volume":"224","author":"Nishioka","year":"2012","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib235","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1476-5381.2012.02102.x","article-title":"Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib236","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijcard.2014.09.016","article-title":"Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells","volume":"177","author":"Brenner","year":"2014","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib237","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2337\/dc10-0187","article-title":"The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha","volume":"33","author":"Fadini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2025.100082_bib238","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijcard.2015.11.180","article-title":"Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: a double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial)","volume":"205","author":"Brenner","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib239","doi-asserted-by":"crossref","first-page":"BR35","DOI":"10.12659\/MSM.881383","article-title":"Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation","volume":"17","author":"Xiao-Yun","year":"2011","journal-title":"Med Sci Monit"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib240","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMcibr2409089","article-title":"Discovery of GLP-1-based drugs for the treatment of obesity","volume":"392","author":"Drucker","year":"2024","journal-title":"N Engl J Med"},{"issue":"6706","key":"10.1016\/j.pharmr.2025.100082_bib241","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib242","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175634","article-title":"The GLP-1 journey: from discovery science to therapeutic impact","volume":"134","author":"Drucker","year":"2024","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib243","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41573-025-01231-3","article-title":"Author correction: GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib244","first-page":"501","article-title":"Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite","volume":"59","author":"Nowak","year":"2008","journal-title":"J Physiol Pharmacol"},{"issue":"Pt 19","key":"10.1016\/j.pharmr.2025.100082_bib245","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1113\/jphysiol.2009.175067","article-title":"Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions","volume":"587","author":"Holmes","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmr.2025.100082_bib246","article-title":"GLP-1R agonists: recent advances, current gaps, and future challenges","author":"Saran","year":"2025","journal-title":"Mol Divers"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100082_bib255","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1042\/CS20171299","article-title":"Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review","volume":"132","author":"Boyle","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.pharmr.2025.100082_bib256","article-title":"Anti-inflammatory benefits of semaglutide: state of the art","volume":"36","author":"Yaribeygi","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"42","key":"10.1016\/j.pharmr.2025.100082_bib257","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1074\/jbc.REV120.008387","article-title":"Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks","volume":"295","author":"Perry","year":"2020","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100082_bib258","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021949","article-title":"SGLT2 inhibition on cardiac mitochondrial function: searching for a sweet spot","volume":"10","author":"Sawicki","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib247","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmr.2025.100082_bib248","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1749-6632.2000.tb06311.x","article-title":"Roles of the AGE-RAGE system in vascular injury in diabetes","volume":"902","author":"Yamamoto","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib249","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib250","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100082_bib251","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib252","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib253","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015323","article-title":"Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Hu","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib254","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7570\/jomes21061","article-title":"Effect of Sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis","volume":"30","author":"Cho","year":"2021","journal-title":"J Obes Metab Syndr"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100082_bib259","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100082_bib260","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jenvrad.2016.06.002","article-title":"Environmental risks of radioactive discharges from a low-level radioactive waste disposal site at Dessel, Belgium","volume":"162-163","author":"Batlle","year":"2016","journal-title":"J Environ Radioact"},{"issue":"10193","key":"10.1016\/j.pharmr.2025.100082_bib261","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib262","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100082_bib263","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1464-5491.2009.02783.x","article-title":"Factors contributing to terminal digital preference in 91,398 patients with diabetes mellitus in Germany and Austria: possible impact on therapeutic decisions","volume":"26","author":"Dost","year":"2009","journal-title":"Diabetic Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib264","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model","volume":"10","author":"Gaspari","year":"2013","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.pharmr.2025.100082_bib265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejim.2023.04.005","article-title":"Tirzepatide decreases systolic and diastolic blood pressure","volume":"114","author":"Copur","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib266","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","article-title":"The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis","volume":"83","author":"Wu","year":"2024","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib267","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib268","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13300-024-01678-4","article-title":"Cardiovascular events in adults with type 2 diabetes and ASCVD initiating once-weekly semaglutide vs DPP-4is in the USA","volume":"16","author":"Inzucchi","year":"2025","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib269","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","article-title":"The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial","volume":"8","author":"Gerstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-021-00873-9","article-title":"Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke","volume":"116","author":"Nizari","year":"2021","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib271","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib272","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib273","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ehf2.12334","article-title":"Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial","volume":"5","author":"Sharma","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib274","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib275","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100082_bib276","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100082_bib277","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib278","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100082_bib279","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"10456","key":"10.1016\/j.pharmr.2025.100082_bib280","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib281","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100082_bib282","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib283","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10157","key":"10.1016\/j.pharmr.2025.100082_bib284","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100082_bib285","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib286","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2025.100082_bib287","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1475-2840-13-32","article-title":"The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms","volume":"13","author":"Zeng","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib288","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100082_bib289","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1093\/eurheartj\/ehv301","article-title":"Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database","volume":"36","author":"Fadini","year":"2015","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib290","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","article-title":"A multicenter observational study of incretin-based drugs and heart failure","volume":"374","author":"Filion","year":"2016","journal-title":"N Engl J Med"},{"issue":"39","key":"10.1016\/j.pharmr.2025.100082_bib291","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100082_bib292","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib293","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100082_bib294","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100082_bib295","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100082_bib296","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100082_bib297","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100082_bib298","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib299","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Empa-Kidney Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib300","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100082_bib301","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100082_bib302","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.124.324823","article-title":"SGLT2 Inhibitors act independently of SGLT2 to confer benefit for HFrEF in mice","volume":"135","author":"Berger","year":"2024","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib303","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib304","first-page":"318","article-title":"Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist","volume":"23","author":"Gerstein","year":"2021","journal-title":"DiabetesObes Metab"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib305","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Frias","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2025.100082_bib306","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100082_bib307","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/antiox10091379","article-title":"Effects of a 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on oxidant and antioxidant biomarkers in patients with type 2 diabetes","volume":"10","author":"Lambadiari","year":"2021","journal-title":"Antioxidants"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100082_bib308","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100082_bib309","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247307","article-title":"Association of body mass index with health care expenditures in the United States by age and sex","volume":"16","author":"Ward","year":"2021","journal-title":"PLoS One"},{"issue":"7 Suppl","key":"10.1016\/j.pharmr.2025.100082_bib311","first-page":"s176","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am J Manag Care"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib312","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/a-1844-1176","article-title":"The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis","volume":"54","author":"Guo","year":"2022","journal-title":"Horm Metab Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100082_bib313","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289616","article-title":"The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2023","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100082_bib314","article-title":"FDA-approved pharmacotherapy for weight loss over the last decade","volume":"14","author":"Idrees","year":"2022","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib315","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib316","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes Sci Pract"},{"issue":"36","key":"10.1016\/j.pharmr.2025.100082_bib317","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"37","key":"10.1016\/j.pharmr.2025.100082_bib318","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib319","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib320","doi-asserted-by":"crossref","first-page":"51","DOI":"10.31083\/j.rcm.2018.02.021","article-title":"Inhibition of the sodium-proton antiporter (exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2","volume":"19","author":"McCullough","year":"2018","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pharmr.2025.100082_bib321","doi-asserted-by":"crossref","unstructured":"Zhao X. Huang K. Zheng M. Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord 2019;19(1):4. https:\/\/doi.org\/10.1186\/s12902-018-0332-5","DOI":"10.1186\/s12902-018-0332-5"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib322","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1038\/s41598-024-55724-z","article-title":"The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function","volume":"14","author":"Wajdlich","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib323","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metabol"},{"key":"10.1016\/j.pharmr.2025.100082_bib324","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.physbeh.2013.04.003","article-title":"Role of central glucagon-like peptide-1 in stress regulation","volume":"122","author":"Ghosal","year":"2013","journal-title":"Physiol Behav"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib325","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/07435800.2012.662664","article-title":"A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy","volume":"37","author":"Meguro","year":"2012","journal-title":"Endocr Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib326","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jash.2012.02.003","article-title":"Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies","volume":"6","author":"Brown","year":"2012","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100082_bib327","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/HJH.0000000000000782","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"34","author":"Zhang","year":"2016","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib328","doi-asserted-by":"crossref","first-page":"C972","DOI":"10.1152\/ajpcell.00246.2023","article-title":"Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone","volume":"325","author":"Ribeiro-Silva","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"issue":"Suppl 2","key":"10.1016\/j.pharmr.2025.100082_bib332","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100082_bib333","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2025.100082_bib334","doi-asserted-by":"crossref","first-page":"108503","DOI":"10.1016\/j.pharmthera.2023.108503","article-title":"A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy","volume":"249","author":"Ashfaq","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100082_bib335","author":"Kasina"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib336","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4183\/aeb.2018.473","article-title":"DPP-4 inhibitors increase the incidence of arthritis\/arthralgia but do not affect autoimmunity","volume":"14","author":"Sayiner","year":"2018","journal-title":"Acta Endocrinol (Buchar)"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib337","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3391","article-title":"DPP-4 inhibitor treatment and the risk of bullous pemphigoid: a systematic review and meta-analysis","volume":"37","author":"Yang","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100082_bib339","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100082_bib340","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100082_bib343","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Int Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib344","doi-asserted-by":"crossref","first-page":"751","DOI":"10.34067\/KID.0000472021","article-title":"Lower urinary tract symptoms should be queried when initiating sodium glucose cotransporter 2 inhibitors","volume":"2","author":"Krepostman","year":"2021","journal-title":"Kidney360"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100082_bib345","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/07853890701854702","article-title":"Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction","volume":"40","author":"Munzel","year":"2008","journal-title":"Ann Med"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100082_bib346","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","article-title":"Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease","volume":"101","author":"Schachinger","year":"2000","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100082_bib347","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/01.CIR.0000093661.90582.c4","article-title":"Oxidative stress and cardiovascular injury: part II: animal and human studies","volume":"108","author":"Griendling","year":"2003","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100082_bib348","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/01.CIR.0000093660.86242.BB","article-title":"Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS","volume":"108","author":"Griendling","year":"2003","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100082_bib349","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1093\/eurheartj\/ehq396","article-title":"Is oxidative stress a therapeutic target in cardiovascular disease?","volume":"31","author":"Munzel","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib350","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.CIR.0000080378.96063.23","article-title":"Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries","volume":"108","author":"Zhang","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100082_bib351","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.freeradbiomed.2012.05.027","article-title":"Actions of \u201cantioxidants\u201d in the protection against atherosclerosis","volume":"53","author":"Lonn","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmr.2025.100082_bib352","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174998","article-title":"Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: a bedside-to-bench approach","volume":"925","author":"Mikkelsen","year":"2022","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100082_bib353","first-page":"65","article-title":"Expert group consensus opinion: role of anti-inflammatory agents in the management of type-2 diabetes (T2D)","volume":"67","author":"Das","year":"2019","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100082_bib354","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40256-024-00673-1","article-title":"SGLT2 inhibitors and how they work beyond the glucosuric effect. state of the art","volume":"24","author":"Aristizabal-Colorado","year":"2024","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725074903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:02:38Z","timestamp":1777456958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725074903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":347,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0031699725074903"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100082","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100082"}}